Biopharma | May 06, 2026
Emcure crosses US$1 billion revenue milestone in FY26; PAT rises 33%
Pharma major reports FY26 revenue of Rs 9,204 crore with 16.6% growth
Pharma major reports FY26 revenue of Rs 9,204 crore with 16.6% growth
Fresenius Kabi's approved generic therapy addresses acute symptomatic hypocalcemia and targets a US market valued at nearly $71 million
The approval enables the company to directly sell health insurance plans to individuals and families while integrating its managed healthcare delivery model into retail offerings
The platform offers personalised recovery plans, AI-driven movement tracking, and access to certified physiotherapists for more than 250 conditions
More than 3,500 participants will join the nationwide AI-focused hackathon hosted as Indian Institute of Science
The company has also launched Elyara, a portfolio of products in regenerative medical aesthetics focused on non-invasive skin and hair restoration
AI-enabled technology platform delivers integrated pharmacovigilance solutions with measurable efficiency gains and enhanced compliance
Designed for high-throughput genomic analysis, the laboratory enables accurate, consistent, and scalable testing, delivering high standards of reporting excellence
Approval marks the second generic semaglutide clearance in Canada and strengthens OneSource’s position in complex injectable CDMO programs
Report highlights growing confidence in digitalisation and AI, even as healthcare leaders remain concerned about workforce gaps, cybersecurity, and data readiness
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
